What do the “new” Pulmonary Hypertension Guidelines tell us: should we change our practice?

On the con- trary, a pilot study to evaluate the effects of losartan on PAP, exercise capacity, quality of life, arterial blood gases and safety did not demonstrate any benefit

All these trials, except CONTAK-CD and MIRACLE-ICD included patients with severe heart failure (NYHA Class III or IV) on optimal drug therapy with left ventricular

A Case of Sjögren’s Syndrome-Related Pulmonary Arterial Hypertension Treated with Iloprost and Bosentan Combination Therapy | Baha et al.. The incidence of SRP

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence

Several characteristics have made rivaroxaban an attractive alternative to warfarin: once-daily dosing, obviating the need for monitoring the international normalized ratio

In 10 of 33 patients in the metabolic group, vitamin B12 deficiency was detected and its rate compared to the total patient number was 2.5%.. Parathyroid adenoma was iden- tified

The most important novelty of the 2018 Hypertension Guide- lines of the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) (1) is the decision to

In this group of patients with sPESI= 0, initial and maintenance treatment (without hospitalization) with rivaroxaban, apixaban and enoxaparine decreased the costs